Jakob Stenman

Jakob Stenman

Senior Lecturer/Senior Physician | Docent
Visiting address: Tomtebodavägen 18A, 17177 Stockholm
Postal address: K6 Kvinnors och barns hälsa, K6 Barnonkologi och Barnkirurgi Stenman, 171 77 Stockholm
Part of:

About me

  • Paediatric surgeon with a background in transplantation surgery and molecular biology research. Clinical Lead for Surgical Oncology at the Department of Pediatric Surgery, Karolinska University Hospital. Principal Investigator at the Pediatric Cancer Research Unit, Karolinska Institutet with a focus on development and implementation of targeted radio-pharmaceutical therapy for neuroblastoma. Chief Investigator of the LuDO-N Trial, a phase II clinical trial assessing radio-pharmaceutical therapy with single agent 177-Lutetium-DOTATATE for relapsed or refractory neuroblastoma in children. Member of the SIOPEN Surgical and Clinical Trials Committees and a board member of the Nordic Society for Paediatric Haematology and Oncology (NOPHO).

Research

  • My research focuses on improving survival and reducing long term morbidity after treatment for solid tumors in children.

    I currently lead the LuDO-N Trial (A phase II trial of 177-Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma, EudraCT: 2020-004445-36). LuDO-N is a Nordic Society for Paediatric Haematology and Oncology (NOPHO) clinical trial, sponsored by the Karolinska University Hospital. The trial is conducted in collaboration with the Prinses Máxima Centrum voor kinderoncologie in The Netherlands and the University College London Hospitals NHS Foundation Trust in the UK. The trial is funded by Barncancerfonden, Cancerfonden, Region Stockholm, Cancer Research UK (CRUK) and by Advanced Accelerator Applications, a Novartis company.

    I have recently initiated a research collaboration with Advanced Accelerator Applications / Novartis to develop the next generation of radiopharmaceutical therapy for neuroblastoma. The project will span over 3 years and involve researchers Kasper Karlsson, Thuy A. Tran and Ninib Baryawno at Karolinska Institutet / SciLifeLab Stockholm as well as Marika Nestor and Fredrik J Swartling at Uppsala University / SciLifeLab Uppsala. We hope that this project will result in a new radiopharmaceutical being brought into clinical trials.

    Finally, I am engaged in the implementation and development of brachytherapy, in combination with organ-sparing surgery, for rhabdomyosarcoma in the bladder and prostate. This technique has been pioneered at the Hôpital Bicêtre and Institute Gustave Roussy in Paris. We have shown that equally high survival rates, with acceptable side effects, can be achieved using high dose rate (HDR) brachytherapy. Further refinements of the surgical technique for catheter placement is ongoing.

Selected publications

Articles

All other publications

Grants

  • Swedish Research Council
    1 December 2023 - 30 November 2026
    Neuroblastoma is the most common and most devastating solid tumor in children. Despite intensive multimodal therapy, long-term survival in high-risk disease is only 50% and chances of survival after a relapse are dismal. Neuroblastoma is a radio-sensitive tumor, making targeted radiopharmaceutical therapy attractive, by delivering radiation to the cancer cells, wherever they reside in the body. We are leading a European multicenter trial where the efficacy of radiopharmaceutical therapy with 177-Lutetium, is being assessed in high-risk neuroblastoma in children (LuDO-N trial). One of the greatest challenges is that patients who experience a relapse are severely weakened by the cancer and by previous therapy, and optimally this type of treatment should be given at an earlier time point. For this purpose, we aim to develop radio-pharmaceutical therapy based on 225-actinium or 211-astathine, that emits a significantly higher radiation energy within a very congined space, to deplete single, or small clusters of metastatic cells and thus prevent metastatic relapses. The overriding aim is to generate data to support a future clinical trial that utilises targeted α-particle therapy early in the course of the disease. By controlling the systemic disease early, we believe that the cure rates in high-risk neuroblastoma could be significantly improved. We aim to translate our results into a clinical trial in humans, within a time period of 5-10 years.

Employments

  • Senior Lecturer/Senior Physician, Department of Women's and Children's Health, Karolinska Institutet, 2024-

Degrees and Education

  • Docent, Pediatric surgery, Karolinska Institutet, 2016

News from KI

Events from KI